U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Platinum-Resistant Ovarian Carcinoma

MedGen UID:
1771608
•Concept ID:
C5418767
•
Neoplastic Process

Definition

The reemergence of platinum-resistant ovarian carcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Platinum-Resistant Ovarian Carcinoma

Professional guidelines

PubMed

Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
Wolford JE, Bai J, Moore KN, Kristeleit R, Monk BJ, Tewari KS
Gynecol Oncol 2020 May;157(2):500-507. Epub 2020 Mar 13 doi: 10.1016/j.ygyno.2020.02.030. PMID: 32173049Free PMC Article

Recent clinical studies

Etiology

The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Peled Y, Levavi H, Krissi H, Weill Y, Sabah G, Eitan R
Am J Clin Oncol 2013 Oct;36(5):472-4. doi: 10.1097/COC.0b013e3182549399. PMID: 22706176
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG, Tian C, Bookman MA
Gynecol Oncol 2010 May;117(2):324-9. Epub 2010 Feb 24 doi: 10.1016/j.ygyno.2010.01.040. PMID: 20185168

Therapy

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C
Gynecol Oncol 2018 Sep;150(3):471-477. Epub 2018 Jul 27 doi: 10.1016/j.ygyno.2018.07.018. PMID: 30060963
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS
Gynecol Oncol 2013 Feb;128(2):221-8. Epub 2012 Sep 5 doi: 10.1016/j.ygyno.2012.08.039. PMID: 22960352
The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Peled Y, Levavi H, Krissi H, Weill Y, Sabah G, Eitan R
Am J Clin Oncol 2013 Oct;36(5):472-4. doi: 10.1097/COC.0b013e3182549399. PMID: 22706176
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG, Tian C, Bookman MA
Gynecol Oncol 2010 May;117(2):324-9. Epub 2010 Feb 24 doi: 10.1016/j.ygyno.2010.01.040. PMID: 20185168
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI
Clin Cancer Res 2004 Sep 15;10(18 Pt 1):6080-5. doi: 10.1158/1078-0432.CCR-04-0574. PMID: 15447993

Prognosis

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C
Gynecol Oncol 2018 Sep;150(3):471-477. Epub 2018 Jul 27 doi: 10.1016/j.ygyno.2018.07.018. PMID: 30060963
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS
Gynecol Oncol 2013 Feb;128(2):221-8. Epub 2012 Sep 5 doi: 10.1016/j.ygyno.2012.08.039. PMID: 22960352
The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma.
Peled Y, Levavi H, Krissi H, Weill Y, Sabah G, Eitan R
Am J Clin Oncol 2013 Oct;36(5):472-4. doi: 10.1097/COC.0b013e3182549399. PMID: 22706176
Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG, Tian C, Bookman MA
Gynecol Oncol 2010 May;117(2):324-9. Epub 2010 Feb 24 doi: 10.1016/j.ygyno.2010.01.040. PMID: 20185168

Clinical prediction guides

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C
Gynecol Oncol 2018 Sep;150(3):471-477. Epub 2018 Jul 27 doi: 10.1016/j.ygyno.2018.07.018. PMID: 30060963

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...